BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 27529842)

  • 1. LAMC2 is a predictive marker for the malignant progression of leukoplakia.
    Nguyen CT; Okamura T; Morita KI; Yamaguchi S; Harada H; Miki Y; Izumo T; Kayamori K; Yamaguchi A; Sakamoto K
    J Oral Pathol Med; 2017 Mar; 46(3):223-231. PubMed ID: 27529842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical study of p21 and Bcl-2 in leukoplakia, oral submucous fibrosis and oral squamous cell carcinoma.
    Sutariya RV; Manjunatha BS
    J Exp Ther Oncol; 2016 Nov; 11(4):285-292. PubMed ID: 27849339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stathmin! An immunohistochemical analysis of the novel marker in Oral Squamous Cell Carcinoma and Oral Leukoplakia.
    Vadla P; Yeluri S; Deepthi G; Guttikonda VR; Taneeru S; Naramala S
    Asian Pac J Cancer Prev; 2020 Nov; 21(11):3317-3323. PubMed ID: 33247690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD133 expression in oral lichen planus correlated with the risk for progression to oral squamous cell carcinoma.
    Sun L; Feng J; Ma L; Liu W; Zhou Z
    Ann Diagn Pathol; 2013 Dec; 17(6):486-9. PubMed ID: 23911820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical location of the p75 neurotrophin receptor (p75NTR) in oral leukoplakia and oral squamous cell carcinoma.
    Kiyosue T; Kawano S; Matsubara R; Goto Y; Hirano M; Jinno T; Toyoshima T; Kitamura R; Oobu K; Nakamura S
    Int J Clin Oncol; 2013 Feb; 18(1):154-63. PubMed ID: 22170235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The combination of SMAD4 expression and histological grade of dysplasia is a better predictor for the malignant transformation of oral leukoplakia.
    Xia RH; Song XM; Wang XJ; Li J; Mao L
    PLoS One; 2013; 8(6):e66794. PubMed ID: 23826135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteopontin: a marker for invasive oral squamous cell carcinoma but not for potentially malignant epithelial dysplasias.
    Routray S; Kheur SM; Kheur M
    Ann Diagn Pathol; 2013 Oct; 17(5):421-4. PubMed ID: 23711950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibroblast Growth Factor (FGF-2) and Its Receptors FGFR-2 and FGFR-3 May Be Putative Biomarkers of Malignant Transformation of Potentially Malignant Oral Lesions into Oral Squamous Cell Carcinoma.
    Nayak S; Goel MM; Makker A; Bhatia V; Chandra S; Kumar S; Agarwal SP
    PLoS One; 2015; 10(10):e0138801. PubMed ID: 26465941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of cornulin, keratin 4, keratin 13 expression and grade of dysplasia for predicting malignant progression of oral leukoplakia.
    Schaaij-Visser TB; Bremmer JF; Braakhuis BJ; Heck AJ; Slijper M; van der Waal I; Brakenhoff RH
    Oral Oncol; 2010 Feb; 46(2):123-7. PubMed ID: 20036603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accumulation of the p53 tumor-suppressor gene product in oral leukoplakia.
    Wood MW; Medina JE; Thompson GC; Houck JR; Min KW
    Otolaryngol Head Neck Surg; 1994 Dec; 111(6):758-63. PubMed ID: 7527509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical detection of p53 and p63 in oral squamous cell carcinoma, oral leukoplakia, and oral submucous fibrosis.
    Varun BR; Ranganathan K; Rao UK; Joshua E
    J Investig Clin Dent; 2014 Aug; 5(3):214-9. PubMed ID: 23776093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of bcl-2 oncoprotein in oral potentially malignant disorders and squamous cell carcinoma: an immunohistochemical study.
    Sudha VM; Hemavathy S
    Indian J Dent Res; 2011; 22(4):520-5. PubMed ID: 22124045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. E-cadherin as a potential biomarker of malignant transformation in oral leukoplakia: a retrospective cohort study.
    von Zeidler SV; de Souza Botelho T; Mendonça EF; Batista AC
    BMC Cancer; 2014 Dec; 14():972. PubMed ID: 25518919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of stromal myofibroblasts in oral leukoplakia, oral submucous fibrosis, and oral squamous cell carcinoma--an immunohistochemical study.
    Gupta K; Metgud R; Gupta J
    J Cancer Res Ther; 2015; 11(4):893-8. PubMed ID: 26881537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of FAP in Oral Leukoplakia and Oral Squamous Cell Carcinoma.
    Li R; Zhang R; Shi X; Jiao X; Li Y; Zhao Y; Liu T; Zhang C
    Int Dent J; 2024 Jun; 74(3):581-588. PubMed ID: 38278714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of MAGE-A expression predicts malignant transformation of oral leukoplakia.
    Ries J; Agaimy A; Vairaktaris E; Gorecki P; Neukam FW; Strassburg LH; Nkenke E
    Cancer Invest; 2012 Aug; 30(7):495-502. PubMed ID: 22646284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression and oncogenic properties of membranous Notch1 in oral leukoplakia and oral squamous cell carcinoma.
    Ding X; Zheng Y; Wang Z; Zhang W; Dong Y; Chen W; Li J; Chu W; Zhang W; Zhong Y; Mao L; Song X; Wu Y
    Oncol Rep; 2018 Jun; 39(6):2584-2594. PubMed ID: 29620248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Expression of Prion protein and its clinical significance in oral squamous cells carcinoma and oral leukoplakia].
    Zhang J; Zeng Y; Zheng J; Xu J
    Zhonghua Kou Qiang Yi Xue Za Zhi; 2013 Dec; 48(12):752-4. PubMed ID: 24495728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-37 expression and its potential role in oral leukoplakia and oral squamous cell carcinoma.
    Lin L; Wang J; Liu D; Liu S; Xu H; Ji N; Zhou M; Zeng X; Zhang D; Li J; Chen Q
    Sci Rep; 2016 May; 6():26757. PubMed ID: 27225603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MCM3 could be a better marker than Ki-67 for evaluation of dysplastic oral lesions: an immunohistochemical study.
    Lameira AG; Pontes FS; Guimarães DM; Alves AC; de Jesus AS; Pontes HA; Pinto Ddos S
    J Oral Pathol Med; 2014 Jul; 43(6):427-34. PubMed ID: 24456424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.